LT3241843T - Imuninių rišiklių tirpumo optimizavimas - Google Patents

Imuninių rišiklių tirpumo optimizavimas

Info

Publication number: LT3241843T
Authority: LT; Lithuania
Prior art keywords: immunobinders; solubility optimization; solubility; optimization
Prior art date: 2008-06-25

Application number

LTEP17161990.1T

Other languages

English (en)

Inventor

Leonardo Borras

David Urech

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-06-25

Filing date

2009-06-25

Publication date

2021-09-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41228195&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3241843(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-06-25 Application filed by Novartis Ag filed Critical Novartis Ag

2021-09-27 Publication of LT3241843T publication Critical patent/LT3241843T/lt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oil, Petroleum & Natural Gas (AREA)
Dermatology (AREA)
Mycology (AREA)
Microbiology (AREA)
Transplantation (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Saccharide Compounds (AREA)

LTEP17161990.1T 2008-06-25 2009-06-25 Imuninių rišiklių tirpumo optimizavimas LT3241843T (lt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US7569208P	2008-06-25	2008-06-25

Publications (1)

Publication Number	Publication Date
LT3241843T true LT3241843T (lt)	2021-09-27

Family

ID=41228195

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
LTEP17161990.1T LT3241843T (lt)	2008-06-25	2009-06-25	Imuninių rišiklių tirpumo optimizavimas
LTEP09768694.3T LT2307455T (lt)	2008-06-25	2009-06-25	Imuninių rišiklių tirpumo optimizavimas

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
LTEP09768694.3T LT2307455T (lt)	2008-06-25	2009-06-25	Imuninių rišiklių tirpumo optimizavimas

Country Status (21)

Country	Link
US (3)	US9556265B2 (lt)
EP (2)	EP3241843B1 (lt)
JP (3)	JP5745720B2 (lt)
KR (2)	KR101650165B1 (lt)
CN (2)	CN102076715B (lt)
AU (1)	AU2009264566B2 (lt)
BR (1)	BRPI0914666A2 (lt)
CA (1)	CA2728829C (lt)
CY (2)	CY1119626T1 (lt)
DK (2)	DK2307455T3 (lt)
ES (2)	ES2884117T3 (lt)
HR (2)	HRP20171250T1 (lt)
HU (2)	HUE056090T2 (lt)
LT (2)	LT3241843T (lt)
MX (2)	MX2011000074A (lt)
PL (2)	PL2307455T3 (lt)
PT (2)	PT3241843T (lt)
RU (3)	RU2514658C2 (lt)
SI (2)	SI3241843T1 (lt)
WO (1)	WO2009155725A1 (lt)
ZA (1)	ZA201008595B (lt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3858854A1 (en)	2008-06-25	2021-08-04	Novartis AG	Stable and soluble antibodies inhibiting tnf
HUE038432T2 (hu)	2008-06-25	2018-10-29	Esbatech Alcon Biomed Res Unit	Nyúl antitestek humanizálása egy univerzális antitest keret alkalmazásával
PL2307454T3 (pl)	2008-06-25	2017-07-31	Esbatech, An Alcon Biomedical Research Unit Llc	Trwałe i rozpuszczalne przeciwciała hamujące VEGF
AU2009264566B2 (en)	2008-06-25	2014-05-08	Novartis Ag	Solubility optimization of immunobinders
US8399625B1 (en)	2009-06-25	2013-03-19	ESBATech, an Alcon Biomedical Research Unit, LLC	Acceptor framework for CDR grafting
AU2014262201B2 (en) *	2009-12-23	2016-09-15	Novartis Ag	Method for decreasing immunogenicity
RU2585534C2 (ru) *	2009-12-23	2016-05-27	ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи	Способ снижения иммуногенности
UY33679A (es)	2010-10-22	2012-03-30	Esbatech	Anticuerpos estables y solubles
JP2014505698A (ja) *	2011-02-02	2014-03-06	グラクソグループリミテッド	新規抗原結合タンパク質
MX2015005384A (es)	2012-11-05	2015-10-09	Delenex Therapeutics Ag	Miembros de union para il-1 beta.
ES2895848T3 (es)	2012-12-17	2022-02-22	Cell Medica Inc	Anticuerpos contra IL-1 beta
CA2894918A1 (en) *	2013-02-15	2014-08-21	Esbatech - A Novartis Company Llc	Acceptor framework for cdr grafting
CN104884471A (zh) *	2013-02-20	2015-09-02	艾斯巴技术-诺华有限责任公司	用于cdr移植的受体框架
KR20160042438A (ko)	2013-08-12	2016-04-19	제넨테크, 인크.	보체-연관 상태의 치료를 위한 조성물 및 방법
WO2015032776A1 (en) *	2013-09-06	2015-03-12	F. Hoffmann-La Roche Ag	Method for improving antibody stability
JP2017515811A (ja)	2014-05-01	2017-06-15	ジェネンテック，インコーポレイテッド	抗ｄ因子抗体変異体及びその使用法
EP3159346B1 (en) *	2015-10-21	2018-07-04	Trinseo Europe GmbH	Aminosilane-functionalized dienes for use in functionalization of elastomeric polymers
BR112018067696A2 (pt)	2016-02-25	2019-01-08	Cell Medica Switzerland Ag	membros de ligação à pd-l1
JP2024508736A (ja)	2021-02-12	2024-02-28	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	補体ｃ３抗原結合タンパク質
EP4304725A1 (en)	2021-03-09	2024-01-17	CDR-Life AG	Rabbit-derived antigen binding protein nucleic acid libraries
EP4304726A1 (en)	2021-03-09	2024-01-17	CDR-Life AG	Mage-a4 peptide-mhc antigen binding proteins
CA3240046A1 (en)	2021-12-14	2023-06-22	Cdr-Life Ag	Dual mhc-targeting t cell engager
WO2024056758A1 (en)	2022-09-14	2024-03-21	Cdr-Life Ag	Mage-a4 peptide dual t cell engagers

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5824307A (en)	1991-12-23	1998-10-20	Medimmune, Inc.	Human-murine chimeric antibodies against respiratory syncytial virus
US5714350A (en)	1992-03-09	1998-02-03	Protein Design Labs, Inc.	Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5736137A (en)	1992-11-13	1998-04-07	Idec Pharmaceuticals Corporation	Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
EP0752248B1 (en)	1992-11-13	2000-09-27	Idec Pharmaceuticals Corporation	Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US6740734B1 (en)	1994-01-14	2004-05-25	Biovitrum Ab	Bacterial receptor structures
DE69721548T2 (de)	1996-02-09	2004-04-01	Abbott Laboratories(Bermuda)Ltd.	HUMANE ANTIKÖRPER WELCHE AN HUMANEN TNFalpha BINDEN
CA2267620A1 (en) *	1996-07-16	1998-01-22	Andreas Pluckthun	Immunoglobulin superfamily domains and fragments with increased solubility
US6884879B1 (en)	1997-04-07	2005-04-26	Genentech, Inc.	Anti-VEGF antibodies
EP2380906A2 (en)	1997-06-12	2011-10-26	Novartis International Pharmaceutical Ltd.	Artificial antibody polypeptides
DE19742706B4 (de)	1997-09-26	2013-07-25	Pieris Proteolab Ag	Lipocalinmuteine
PT1974747E (pt)	1998-08-11	2012-09-05	Biogen Idec Inc	Terapias de combinação para linfomas de células b compreendendo a administração de anticorpo anti-cd20
US6818418B1 (en)	1998-12-10	2004-11-16	Compound Therapeutics, Inc.	Protein scaffolds for antibody mimics and other binding proteins
SE9901379D0 (sv)	1999-04-19	1999-04-19	Pharmacia & Upjohn Ab	Receptor structures
US6602977B1 (en)	1999-04-19	2003-08-05	Biovitrum Ab	Receptor structures
ATE273323T1 (de)	1999-12-28	2004-08-15	Esbatech Ag	INTRAKÖRPER MIT DEFINIERTER STRUKTUR (ßFRAMEWORKß), DIE IN EINER REDUZIERENDEN UMGEBUNG STABIL IST, UND IHRE VERWENDUNGEN
ATE419354T1 (de) *	2000-02-25	2009-01-15	Us Gov Health & Human Serv	Scfv-moleküle gegen egfrviii mit verbesserter zytotoxizität und ausbeute, darauf basierte immuntoxine, und verfahren zur deren verwendung
WO2002020565A2 (en)	2000-09-08	2002-03-14	Universität Zürich	Collections of repeat proteins comprising repeat modules
DE60236861D1 (de)	2001-04-26	2010-08-12	Amgen Mountain View Inc	Kombinatorische bibliotheken von monomerdomänen
US20030157561A1 (en)	2001-11-19	2003-08-21	Kolkman Joost A.	Combinatorial libraries of monomer domains
US6905608B2 (en)	2002-01-22	2005-06-14	Exergy Technologies Corporation	Advanced electrodeionization for fluid recycling
EP2332989B1 (en)	2002-05-22	2015-04-01	ESBATech, an Alcon Biomedical Research Unit LLC	Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
MXPA05012723A (es) *	2003-05-30	2006-02-08	Genentech Inc	Tratamiento con anticuerpos anti-vgf.
US7691970B2 (en)	2003-08-25	2010-04-06	Pieris Ag	Muteins of a bilin-binding protein with affinity for a given target
NZ550772A (en)	2004-05-21	2009-10-30	Uab Research Foundation	Variable lymphocyte receptors, related polypeptides and nucleic acids, and uses thereof
MX2007015280A (es)	2005-06-07	2008-04-08	Esbatech Ag	Anticuerpos estables y solubles que inhiben tnf-alfa.
ES2603399T3 (es)	2006-07-10	2017-02-27	Esbatech, An Alcon Biomedical Research Unit Llc	Anticuerpos scFv que atraviesan capas epiteliales y/o endoteliales
NZ579594A (en)	2007-03-12	2012-03-30	Esbatech Alcon Biomed Res Unit	Sequence based engineering and optimization of single chain antibodies
CN101849001B (zh)	2007-06-25	2014-07-16	艾斯巴技术-诺华有限责任公司	修饰抗体的方法和具有改善的功能性质的修饰抗体
RU2010102064A (ru)	2007-06-25	2011-07-27	Эсбатек, Эн Элкон Биомедикал Рисёрч Юнит Ллк (Ch)	Способ конструирования, основанный на определении последовательностей, способ оптимизации одноцепочечных антител
AU2009264566B2 (en)	2008-06-25	2014-05-08	Novartis Ag	Solubility optimization of immunobinders

2009
- 2009-06-25 AU AU2009264566A patent/AU2009264566B2/en active Active
- 2009-06-25 EP EP17161990.1A patent/EP3241843B1/en active Active
- 2009-06-25 LT LTEP17161990.1T patent/LT3241843T/lt unknown
- 2009-06-25 PT PT171619901T patent/PT3241843T/pt unknown
- 2009-06-25 MX MX2011000074A patent/MX2011000074A/es active IP Right Grant
- 2009-06-25 RU RU2011102548/10A patent/RU2514658C2/ru active
- 2009-06-25 JP JP2011515050A patent/JP5745720B2/ja active Active
- 2009-06-25 CN CN200980123815.6A patent/CN102076715B/zh active Active
- 2009-06-25 ES ES17161990T patent/ES2884117T3/es active Active
- 2009-06-25 HU HUE17161990A patent/HUE056090T2/hu unknown
- 2009-06-25 BR BRPI0914666A patent/BRPI0914666A2/pt not_active Application Discontinuation
- 2009-06-25 SI SI200932137T patent/SI3241843T1/sl unknown
- 2009-06-25 PT PT97686943T patent/PT2307455T/pt unknown
- 2009-06-25 CN CN201511018105.0A patent/CN105418763A/zh active Pending
- 2009-06-25 CA CA2728829A patent/CA2728829C/en active Active
- 2009-06-25 US US13/000,460 patent/US9556265B2/en active Active
- 2009-06-25 ES ES09768694.3T patent/ES2629345T3/es active Active
- 2009-06-25 SI SI200931674A patent/SI2307455T1/sl unknown
- 2009-06-25 DK DK09768694.3T patent/DK2307455T3/en active
- 2009-06-25 PL PL09768694T patent/PL2307455T3/pl unknown
- 2009-06-25 LT LTEP09768694.3T patent/LT2307455T/lt unknown
- 2009-06-25 KR KR1020117001959A patent/KR101650165B1/ko active IP Right Grant
- 2009-06-25 EP EP09768694.3A patent/EP2307455B1/en not_active Revoked
- 2009-06-25 DK DK17161990.1T patent/DK3241843T3/da active
- 2009-06-25 HU HUE09768694A patent/HUE034827T2/en unknown
- 2009-06-25 WO PCT/CH2009/000221 patent/WO2009155725A1/en active Application Filing
- 2009-06-25 PL PL17161990T patent/PL3241843T3/pl unknown
- 2009-06-25 KR KR1020167017202A patent/KR101790567B1/ko active IP Right Grant
- 2009-06-25 MX MX2013011865A patent/MX346024B/es unknown
2010
- 2010-11-30 ZA ZA2010/08595A patent/ZA201008595B/en unknown
2014
- 2014-02-10 RU RU2014104577A patent/RU2653441C2/ru active
- 2014-03-18 JP JP2014054856A patent/JP2014111667A/ja active Pending
2016
- 2016-04-06 JP JP2016076318A patent/JP2016128517A/ja active Pending
- 2016-12-14 US US15/378,649 patent/US10221237B2/en active Active
2017
- 2017-06-22 CY CY20171100670T patent/CY1119626T1/el unknown
- 2017-08-16 HR HRP20171250TT patent/HRP20171250T1/hr unknown
2018
- 2018-04-05 RU RU2018112257A patent/RU2018112257A/ru not_active Application Discontinuation
2019
- 2019-02-05 US US16/267,460 patent/US11046757B2/en active Active
2021
- 2021-08-25 HR HRP20211356TT patent/HRP20211356T1/hr unknown
- 2021-09-22 CY CY20211100832T patent/CY1124644T1/el unknown

Also Published As

Publication number	Publication date
RU2011102548A (ru)	2012-07-27
PL3241843T3 (pl)	2021-12-27
HRP20171250T1 (hr)	2017-10-20
ES2884117T3 (es)	2021-12-10
SI3241843T1 (sl)	2021-11-30
DK3241843T3 (da)	2021-09-06
AU2009264566B2 (en)	2014-05-08
JP2016128517A (ja)	2016-07-14
EP3241843B1 (en)	2021-07-28
JP5745720B2 (ja)	2015-07-08
CA2728829C (en)	2018-01-02
HRP20211356T1 (hr)	2021-11-26
CN102076715A (zh)	2011-05-25
JP2014111667A (ja)	2014-06-19
KR20110022714A (ko)	2011-03-07
RU2653441C2 (ru)	2018-05-08
PL2307455T3 (pl)	2017-09-29
ZA201008595B (en)	2012-02-29
RU2514658C2 (ru)	2014-04-27
BRPI0914666A2 (pt)	2015-10-20
EP2307455B1 (en)	2017-03-22
CY1124644T1 (el)	2022-07-22
KR101790567B1 (ko)	2017-10-26
AU2009264566A1 (en)	2009-12-30
US9556265B2 (en)	2017-01-31
HUE056090T2 (hu)	2022-01-28
DK2307455T3 (en)	2017-07-10
MX346024B (es)	2017-03-02
CY1119626T1 (el)	2018-04-04
CN102076715B (zh)	2018-06-19
US11046757B2 (en)	2021-06-29
KR20160083129A (ko)	2016-07-11
ES2629345T3 (es)	2017-08-08
KR101650165B1 (ko)	2016-08-22
US10221237B2 (en)	2019-03-05
LT2307455T (lt)	2017-06-26
CA2728829A1 (en)	2009-12-30
HUE034827T2 (en)	2018-03-28
SI2307455T1 (sl)	2017-07-31
PT3241843T (pt)	2021-09-10
CN105418763A (zh)	2016-03-23
RU2018112257A (ru)	2019-10-09
US20170096482A1 (en)	2017-04-06
US20190169284A1 (en)	2019-06-06
MX2011000074A (es)	2011-02-24
JP2011525496A (ja)	2011-09-22
US20110268728A1 (en)	2011-11-03
EP3241843A1 (en)	2017-11-08
PT2307455T (pt)	2017-07-03
EP2307455A1 (en)	2011-04-13
WO2009155725A1 (en)	2009-12-30
RU2014104577A (ru)	2015-08-20

Publication	Publication Date	Title
ZA201008595B (en)	2012-02-29	Solubility optimization of immunobinders
HK1173142A1 (en)	2013-05-10	N1-sulfonyl-5-fluoropyrimidinone derivatives n1--5-
HK1172893A1 (en)	2013-05-03	5-fluoropyrimidinone derivatives 5-
IL219087A0 (en)	2012-06-28	Benzimidazole-imidazole derivatives
IL216007A0 (en)	2012-01-31	Isoxazole-pyridine derivatives
IL215109A0 (en)	2011-12-29	Isoxazole-pyridazine derivatives
IL214941A0 (en)	2011-11-30	Isoxazole-pyrazole derivatives
IL213927A0 (en)	2011-07-31	Deoxyactagardine derivatives
HK1172894A1 (en)	2013-05-03	N1-acyl-5-fluoropyrimidinone derivatives n1--5-
HK1169623A1 (en)	2013-02-01	Pyrazinooxazepine derivatives
IL218500A0 (en)	2012-07-31	Apogossypolone derivatives as anticaner agents
EP2512482A4 (en)	2013-05-22	DERIVATIVES OF 2-ALDOXIMINO-5-FLUOROPYRIMIDINE
HK1173134A1 (en)	2013-05-10	Substituted halophenoxybenzamide derivatives
IL213262A0 (en)	2011-07-31	Tetrahydronaphthalen-2-ol derivatives
GB0912499D0 (en)	2009-08-26	Indopyl-pyridone derivatives
GB0821710D0 (en)	2008-12-31	Derivatives of dihydroindolone
PL386302A1 (pl)	2010-04-26	Nowa pochodna izotiazolopirydyny